Daewoong to file overseas patent application over new dementia treatment
Published: 2009-03-13 06:58:00
Updated: 2009-03-13 06:58:00
Daewoong Pharm and Medifron DBT, a pharmaceutical company specializing in the development of neurological treatments, said on March 10 it will jointly file its patent application of DBT-1339, a novel treatment for Alzheimer's dementia, in 20 countries including the U.S. and Japan.
DBT-1339 is ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
